openPR Logo
Press release

Secondary Progressive MS – Majority MS patients progress to SPMS indicating huge market potential

02-19-2018 11:02 AM CET | Health & Medicine

Press release from: Pharmascroll Research and Consulting Private Limited

Secondary Progressive MS – Majority MS patients progress

Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS.

SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest report by Pharmascroll, SPMS- A Detailed Overview, nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the patients might not have relapses at all but the symptoms may not completely go off (plateau) in the remission period.

As per the current scenario in Multiple Sclerosis indication, there are over 15 molecules approved in the worldwide market. However, majority of the molecules are approved in the Relapsing Remitting form of Multiple Sclerosis. The more progressive forms of Multiple Sclerosis like Secondary Progressive MS and Primary progressive MS are still to encounter the boom in terms of number of launched molecules and hence the indication sales revenue.

However, as per the report SPMS- A Detailed Overview, for Secondary progressive MS, the scenario is changing rapidly. The usage of existing products like Tysabri, Ocrelizumab and Zinbryta in SPMS, expected launch of Siponimod by Novartis in SPMS segment in 2019 and a strong pipeline in progressive MS including the products Laquinimod by Teva, Masitinib by AB Sciences, Ponesimod by Actelion and Lemtrada by Sanofi, indicates a huge paradigm shift for the progressive forms of MS specifically SPMS.

The report provides an overview of SPMS in detail, highlights the SPMS epidemiology in the key geographies (Forecast to 2024), elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecasts till 2030.

Why Purchase the report:
The report would help the pharma companies understand the SPMS indication in detail, identify business opportunities for making short term and long term plans, understand the epidemiology of SPMS, identify the triggers of prescription for the physicians in SPMS and make companies aware of the existing and upcoming competition along with their expected sales revenues and patient numbers in key geographies.

Companies Covered:
Biogen
Novartis
Sanofi Genzyme
Active Biotech
Merck
Teva
Bayer
Actelion
Medday Pharmaceuticals
Santhera Pharmaceuticals
AB Sciences
Roche
Genentech
Medicinova

Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada

Table of Content:
1. Multiple Sclerosis Definition
2. Types of MS
a. RRMS
b. SPMS
c. PPMS
d. PRMS
3. SPMS defined
4. Causes of SPMS
5. Profile of SPMS Patient
6. Symptoms of SPMS
7. Disease progression and impact on QoL
8. Disease Diagnosis
a. Disease diagnosis through symptoms
b. Disease diagnosis through medical tests
9. Disease Epidemiology in US, UK, Germany, Italy, France, Spain, Japan
10. Factors impacting a physician’s prescription decision
a. Efficacy
b. Tolerability and Safety
c. Monitoring Requirements
d. Pricing and Reimbursement
11.Disease Modifying Therapies for SPMS
a. Laquinimod
b. Ocrelizumab
c. Masitinib
d. Lemtrada
e. Tysabri
f. Siponimod
g. Zinbryta
h. Mitoxantrone
i. Ponesimod
12.Drug Attribute Analysis
13. Other Pipeline Products
14. SPMS Market Sizing
a. Brand wise sales and patient numbers worldwide
b. Brand wise value and patient numbers by key geographies/countries
c. Country wise value sales and patient shares for all brands

The report can be checked at www.pharmascroll.com/product/spms-detailed-overview

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

Pharmascroll Research and Consulting Private Ltd
Hyderabad
India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Secondary Progressive MS – Majority MS patients progress to SPMS indicating huge market potential here

News-ID: 946938 • Views: 291

More Releases from Pharmascroll Research and Consulting Private Limited

Pharmascroll offers Social Media Analytics services for Pharmaceutical and Healt …
Pharmascroll, a renowned Market Research and Business Consulting firm, has been offering research services to Healthcare and Pharmaceutical firms since over 3 years. Pharmascroll has published 70+ syndicated reports in multiple disease indications and has served 30+ market research clients in the Pharmaceutical and Healthcare domain. The firm has catered to customers across Global markets including US, Europe and Asian countries. The firm currently offers research services in the areas
Pharmascroll offering Quality Healthcare and Pharmaceutical Market Research serv …
Pharmascroll, a Market Research and Consulting firm, has been a renowned Syndicated and customized research provider across the Healthcare and Pharmaceutical space. Pharmascroll has generated over 75 market research reports in multiple disease indications and has consulted and researched for several Global clients across multiple areas. Global Market Research Industry exceeded 44 Bn USD in revenues in 2015 and around 14% of the market research revenues registered across the Globe
Schizophrenia: Disease Insights & Market Forecasts to 2024 by Pharmascroll
“Schizophrenia: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Schizophrenia disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Schizophrenia, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs
Epilepsy: Disease Insights and Market Forecasts to 2024 by Pharmascroll
“Epilepsy: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Epilepsy, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs

All 5 Releases


More Releases for SPMS

Global Secondary Progressive Multiple Sclerosis (SPMS) by API Manufacturers, Cou …
Researchmoz added Most up-to-date research on "Secondary Progressive Multiple Sclerosis (SPMS)-Global API Manufacturers,Marketed and PhaseIII Drugs Landscape,2018" to its huge collection of research reports. An insight on the important factors and trends influencing the market. "Secondary Progressive Multiple Sclerosis (SPMS)-Global API Manufacturers,Marketed and PhaseIII Drugs Landscape,2018" report provides comprehensive insights about marketed and PhaseIII products for Secondary Progressive Multiple Sclerosis (SPMS) . The report includes information of marketed products including their
Pharmaceutical Growing Inclination of Secondary Progressive Multiple Sclerosis ( …
ResearchMoz presents Professional and In-depth Study of "Secondary Progressive Multiple Sclerosis (SPMS) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025" with coming years Industries Trends, Projections of Global Growth, Major Key Player and Case Study, Review, Share, Size, Effect. ' ' Multiple sclerosis (MS), which is also known as disseminated sclerosis, is an inflammatory disease of the nervous system. It is primarily characterized by the
Pharmaceutical Manufacturers Report of Secondary Progressive Multiple Sclerosis …
Multiple sclerosis (MS), which is also known as disseminated sclerosis, is an inflammatory disease of the nervous system. It is primarily characterized by the disruption of the nerve cells of the spinal cord and the brain, which results in the loss of ability to communicate along with various other physical, mental, and psychiatric problems. Secondary progressive multiple sclerosis (SPMS) is a type of MS that typically follows relapsing-remitting MS (RRMS).
PPMS and SPMS: Epidemiology and Market Forecasts to 2030
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS. SPMS: Epidemiology and Market Forecasts to 2030 SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses
Secondary Progressive Multiple Sclerosis (SPMS) Market Size, Share - Global Indu …
Latest industry research report on: Global Secondary Progressive Multiple Sclerosis Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts. DelveInsight's,Secondary Progressive Multiple Sclerosis (SPMS)-Global API Manufacturers,Marketed and Phase III Drugs Landscape,2018" report provides comprehensive insights about marketed and Phase III products for Secondary Progressive Multiple Sclerosis (SPMS) . The report includes information of marketed products including their product description,patent details,forecasted sales till 2020 & API manufacturer
Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Market Expected to …
Market Research Hub, “Secondary Progressive Multiple Sclerosis Pipeline Insights”, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Secondary Progressive Multiple Sclerosis (SPMS). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Secondary Progressive Multiple Sclerosis (SPMS) by development stage, therapy type, route of administration and molecule type is also covered